VivoSeq
Cardiovascular

Ventricular Tachycardia

29

Pipeline Programs↗

5

Active Trials↗

11

Companies Involved↗

Ventricular Tachycardia is an emerging landscape with 29 programs across 11 companies. The most active players are Vitae Pharmaceuticals Inc., an Allergan affiliate, Pfizer, Astellas. 10 therapies are approved with 4 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

52/100

Pipeline Velocity

0/100

Mech. Concentration

14/100

Completion Rate

50/100

Attrition Rate

37/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

V

Vitae Pharmaceuticals Inc., an Allergan affiliate

1 program

Phase 1Pfizer logo

Pfizer

2 programs

Phase 2Astellas logo

Astellas

2 programs

Phase 3M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

Phase 3Bayer logo

Bayer

1 program

ApprovedBoehringer Ingelheim logo

Boehringer Ingelheim

1 program

Approved

Pipeline

Programs by Phase

Preclinical9

Sotalol

Legacy Health System

Fentanyl

Cephalon

Antiarrhythmic Drug

Yonsei University

Versed

Emory University

Guideline Directed Medical Therapy

IRCCS Policlinico S. Donato

Phase 12

Onabotulinumtoxina

Vitae Pharmaceuticals Inc., an Allergan affiliate

Meta-Hydroxyephedrine Radioactive Tracer

Khaled Awad, MD

Phase 24

Omegaven

University of California, San Diego

GAP-486

Pfizer

Double-Blind Investigational Anti-Arrhythmic

Pfizer

Venous Ethanol

The Methodist Hospital Research Institute

Phase 34

Amiodarone

Wyeth-Lederle Vaccines

Alcohol

Astellas

Adenosine

Astellas

Dexmedetomidine

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Approved10

Aspirin

Bayer

Mexiletine

Boehringer Ingelheim

Verapamil

Val Adams

Remifentanil

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Flecainide

Alvogen Korea

Analysis

Trial Status

27

clinical trials

Completed10 · 37%
Terminated7 · 26%
Recruiting4 · 15%
Withdrawn3 · 11%
Unknown status2 · 7%
Active, not recruiting1 · 4%

Clinical Trials

Trial Activity

27 trials

Venous Ethanol for Ventricular Tachycardia
Recruiting·TThe Methodist Hospital Research Institute·Phase 2·NCT05511246·156 enrolled
MANAGE-VT Registry - MANAGEment of Ventricular Tachycardia Outcomes Registry
Recruiting·CCorVita Science Foundation·N/A·NCT06455488·130 enrolled
Study Evaluating Dexmedetomidine in the Acute Treatment of Electrical Storm
Recruiting·OOttawa Heart Institute Research Corporation·Phase 3·NCT06281977·192 enrolled
Ventricular Tachycardia Substrate Mechanisms Revealed by Local Repolarization and Conduction Parameters
Recruiting·EEmory University·Preclinical·NCT05478213·10 enrolled
Catheter Ablation Versus Anti-arrhythmic Drugs for Ventricular Tachycardia
Active, not recruiting·WWestern Sydney Local Health District·N/A·NCT05524077·162 enrolled
Inducibility and Stability of Ventricular Tachycardia Inpatients Undergoing VT Ablation Under General Anesthesia
Completed·—·N/A·NCT02419547·11 enrolled
Oral Verapamil in Acute Paroxysmal Supra Ventricular Tachycardia(PSVT) Recurrence Control
Completed·TTehran University of Medical Sciences·Phase 4·NCT01655316·90 enrolled
A Trial to Compare American Heart Association (AHA) and Simple (SIM)Method to Give Adenosine to Treat Supra-ventricular Tachycardia (SVT)
Completed·UUniversity of Pretoria·Phase 3·NCT04392362·30 enrolled
Ventricular Tachycardia (VT) Ablation or Escalated Drug Therapy
Completed·—·Phase 4·NCT00905853·260 enrolled
Trial to Evaluate the Efficacy and Safety of Substrate Ablation of Monomorphic Ventricular Tachycardia
Completed·HHospital General Universitario Gregorio Marañon·N/A·NCT03734562·180 enrolled
Radiofrequency Ablation for Polymorphic Ventricular Tachycardia With Heart Failure (RFCA for PMVT-HF)
Completed·—·N/A·NCT07130175·118 enrolled
Antiarrhythmics or Ablation for Ventricular Tachycardia 2
Completed·—·Phase 4·NCT02830360·416 enrolled
Remifentanil Intravenous Patient Controlled Analgesia (IVPCA) for Ablation of Idiopathic Ventricular Tachycardia
Completed·NNYU Langone Health·Phase 4·NCT01901575·16 enrolled
DOACs for Stroke Prevention Post Ventricular Tachycardia Ablation
Completed·KKansas City Heart Rhythm Institute·Phase 4·NCT02666742·246 enrolled
Intravenous n-3 Fatty Acids and Ventricular Tachycardia in Patients With Implantable Cardioverter Defibrillator (ICD)-Pacemaker
Completed·—·Phase 1/2·NCT00534300·8 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)